Reported 5 months ago
The article discusses the comparison between investing in Nvidia and AbbVie, suggesting that while Nvidia has been a great stock, it currently trades at a high valuation that may limit future returns. On the other hand, AbbVie, a healthcare stock, is presented as a promising investment option due to its recent performance despite the decline in sales of its top-selling drug Humira. AbbVie's strategic focus on new drugs, acquisitions, and modest valuation is highlighted as factors that could lead to strong gains for long-term investors, making it a better choice than Nvidia.
Source: YAHOO